Results 111 to 120 of about 11,328,563 (174)

Topography and risk factors of amyloid-related imaging abnormality: real-world data from 168 aducanumab-treated patients at a private clinic in South Korea. [PDF]

Alzheimers Dement (Amst)
Yoon S, Ahn J, Kim S, Kim K, Kim SY, An SK, Na DG, Kim YJ, Kwak K, Seo SW, Na DL.   +10 more
europepmc   +1 more source

Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181. [PDF]

J Prev Alzheimers Dis
Noguchi-Shinohara M, Muramatsu D, Shima A, Sakashita Y, Tada Y, Yamaguchi H, Komatsu J, Ikeda T, Ono K.   +8 more
europepmc   +1 more source

Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. [PDF]

J Clin Med
Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, Koutsouraki E.   +6 more
europepmc   +1 more source

Before the bolus: why anti-amyloid therapy must become part of every stroke code. [PDF]

Ann Med Surg (Lond)
Khaliq AS, Khan K.
europepmc   +1 more source

Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status. [PDF]

Cureus
Rohatgi S, Younan CM, Martinez Imbett RE, Ford JN, Wleklinski M, Zhu S, Romero J.   +6 more
europepmc   +1 more source

Amyloid-Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β-Amyloid Immunotherapy in Alzheimer Disease. [PDF]

J Am Heart Assoc
Greenberg SM, Iadecola C, Chou SH, Cogswell PM, Elkind MSV, Hicks WJ, Le C, Levine DA, Lipton R, Massimo L, Mohl SM, Seshadri S, Snyder HM, Yaffe K, Zachrison KS, ARIA Summit Working Group.   +15 more
europepmc   +1 more source

Evaluation of plasma neurofilament and glial fibrillary acidic protein to predict or detect amyloid related imaging abnormalities. [PDF]

Alzheimers Dement (Amst)
Schwartz NU, Ellingson T, Nguyen H, Lin Z, Ashton NJ, Dage JL, Deniz K, Dietz CD, Ljubenkov PA, Miller BL, Nael K, Possin K, Rojas JC, Rosen HJ, Saloner R, Soleimani-Meigooni DN, Staffaroni AM, Stephens ML, Tammewar G, Wang Y, La Joie R, Rabinovici GD, Boxer AL, VandeVrede L.   +23 more
europepmc   +1 more source

Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab. [PDF]

Neurol Int
Demir ÜF, Karakuş Dilbaz F.
europepmc   +1 more source

Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal. [PDF]

Alzheimers Dement
Tonietto M, Silvestri E, Belder CRS, Barkhof F, Fox NC, Smith J, Klein G.   +6 more
europepmc   +1 more source

Alzheimer's Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations. [PDF]

Clin Interv Aging
Zrineh A, Akwan R, Darawsheh R, Nasser A, Elsharkawy MM.   +4 more
europepmc   +1 more source